Balyasny Asset Management LLC Avadel Pharmaceuticals PLC Transaction History

Balyasny Asset Management LLC

  • $58 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
SELL
$12.55 - $17.22 $5.92 Million - $8.12 Million
-471,803 Reduced 60.37%
309,712 $5.23 Million
Q4 2023

Feb 14, 2024
BUY
$9.64 - $14.59 $7.53 Million - $11.4 Million
781,515 New
781,515 $11 Million
Q3 2020

Nov 16, 2020
SELL
$5.02 - $8.98 $490,388 - $877,229
-97,687 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$7.25 - $11.75 $708,230 - $1.15 Million
97,687 New
97,687 $789,000

Others Institutions Holding AVDL

# of Institutions
8
Shares Held
1.07M
Call Options Held
0
Put Options Held
0
View Full List

About AVADEL PHARMACEUTICALS PLC

AVDL Quotes by TradingView
  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $626M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email